Medical Research Council Technology and Pharmidex Announce Drug Discovery Collaboration
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Medical Research Council Technology (MRCT) and Pharmidex have announced that Pharmidex will provide all in vivo ADME/PK drug discovery support to the MRCT in 2010.
Dr Andy Merritt, Associate Director of Chemistry at MRCT’s Centre for Therapeutics Discovery said, “As we rapidly progress a number of small molecule projects towards proof of concept studies we need to measure pharmaceutical company quality ADME information. By choosing Pharmidex as our supplier of pharmacokinetic and ADME studies we will not only access high quality laboratory services but also gain access to experience and knowledge in a scientific partnership that will enable us to develop efficient, timely, high quality studies to answer key aspects of our programme progressions.”
Dr Gary Manchee, global Head of Business Development at Pharmidex concludes that the advantages that Pharmidex offer as the partner of choice lay in the broad range of services available, the high quality of the data, bespoke study design options, and the expert DMPK advice that comes with the ‘Pharmidex package’. This powerful combination together with the “part of your lab” mentality at Pharmidex and the “quick and direct access” to our scientists working on client projects at all times, ensures responsive, fast and effective lead optimization for our client.
Dr Andy Merritt, Associate Director of Chemistry at MRCT’s Centre for Therapeutics Discovery said, “As we rapidly progress a number of small molecule projects towards proof of concept studies we need to measure pharmaceutical company quality ADME information. By choosing Pharmidex as our supplier of pharmacokinetic and ADME studies we will not only access high quality laboratory services but also gain access to experience and knowledge in a scientific partnership that will enable us to develop efficient, timely, high quality studies to answer key aspects of our programme progressions.”
Dr Gary Manchee, global Head of Business Development at Pharmidex concludes that the advantages that Pharmidex offer as the partner of choice lay in the broad range of services available, the high quality of the data, bespoke study design options, and the expert DMPK advice that comes with the ‘Pharmidex package’. This powerful combination together with the “part of your lab” mentality at Pharmidex and the “quick and direct access” to our scientists working on client projects at all times, ensures responsive, fast and effective lead optimization for our client.
